​
​

Innate Pharma (IPHA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Innate Pharma Revenue Highlights

Latest Revenue (Y)

$51.90M

Latest Revenue (Q)

$16.56M

Innate Pharma Revenue by Period

Innate Pharma Revenue by Year

DateRevenueChange
2023-12-31$51.90M4.56%
2022-12-31$49.64M309.83%
2021-12-31$12.11M-78.69%
2020-12-31$56.83M-17.60%
2019-12-31$68.97M-13.67%
2018-12-31$79.89M144.83%
2017-12-31$32.63M-41.90%
2016-12-31$56.16M213.64%
2015-12-31$17.91M1874.20%
2014-12-31$907.00K-92.73%
2013-12-31$12.47M20.16%
2012-12-31$10.38M-11.61%
2011-12-31$11.74M171.76%
2010-12-31$4.32M-44.01%
2009-12-31$7.72M-40.30%
2008-12-31$12.92M-9.56%
2007-12-31$14.29M130.67%
2006-12-31$6.20M376.54%
2005-12-31$1.30M-

Innate Pharma generated $51.90M in revenue during NA 2023, up 4.56% compared to the previous quarter, and up 64.96% compared to the same period a year ago.

Innate Pharma Revenue by Quarter

DateRevenueChange
2023-12-31$16.56M54.43%
2023-09-30$10.72M-69.67%
2023-06-30$35.34M75.85%
2023-03-31$20.10M141.89%
2022-12-31$8.31M37.51%
2022-09-30$6.04M-85.36%
2022-06-30$41.27M124.63%
2020-06-30$18.37M-

Innate Pharma generated $16.56M in revenue during Q4 2023, up 54.43% compared to the previous quarter, and up 274.01% compared to the same period a year ago.

Innate Pharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
IPHAInnate Pharma$51.90M$16.56M
MOLNMolecular Partners$7.04M$2.74M
DYAIDyadic$2.90M$1.96M
HCWBHCW Biologics$2.84M$426.42K
IPSCCentury Therapeutics$2.23M$791.00K
INBXInhibrx Biosciences$1.80M-
STTKShattuck Labs$1.66M$1.61M
ADXNAddex Therapeutics$1.61M$235.00K
MNOVMediciNova$1.00M-
ANEBAnebulo Pharmaceuticals--
CYTCyteir Therapeutics--
ELYMEliem Therapeutics--
PRDSPardes Biosciences--
CSBRChampions Oncology--

IPHA Revenue FAQ

What is Innate Pharma’s yearly revenue?

Innate Pharma's yearly revenue for 2023 was $51.9M, representing an increase of 4.56% compared to 2022. The company's yearly revenue for 2022 was $49.64M, representing an increase of 309.83% compared to 2021. IPHA's yearly revenue for 2021 was $12.11M, representing a decrease of -78.69% compared to 2020.

What is Innate Pharma’s quarterly revenue?

Innate Pharma's quarterly revenue for Q4 2023 was $16.56M, a 54.43% increase from the previous quarter (Q3 2023), and a 99.27% increase year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $10.72M, a -69.67% decrease from the previous quarter (Q2 2023), and a 77.43% increase year-over-year (Q3 2022). IPHA's quarterly revenue for Q2 2023 was $35.34M, a 75.85% increase from the previous quarter (Q1 2023), and a -14.36% decrease year-over-year (Q2 2022).

What is Innate Pharma’s revenue growth rate?

Innate Pharma's revenue growth rate for the last 3 years (2021-2023) was 328.51%, and for the last 5 years (2019-2023) was -24.75%.